- Conditions
- Advanced Solid Tumor
- Interventions
- YL242, YL242; Pembrolizumab, YL242; 5-FU; LV, YL242; Pembrolizumab; 5-FU
- Drug
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Sarasota, Florida • Boston, Massachusetts + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–205
of 205
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Upper Gastrointestinal Bleeding
- Interventions
- Clinician notification, Clinician Notification with Nurse Facilitation, Clinician Notification / Patient Activation, Clinician Notification with Nurse Facilitation / Patient Activation
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Sudden Cardiac Death, Ventricular Tachycardia, Ventricular Fibrillation, Cardiomyopathy
- Interventions
- Cardiac Sympathetic Denervation (CSD), Routine Care
- Procedure · Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Portland, Oregon • Nashville, Tennessee
- Conditions
- Cardiovascular Diseases, Cardiac Rehabilitation
- Interventions
- Text Messaging, Fully Automated Online Program, Low-Intensity Cardiac Rehabilitation Maintenance Program, High Intensity Cardiac Rehabilitation Maintenance Program
- Behavioral
- Lead sponsor
- The Miriam Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Participants With Advanced Solid Tumor Malignancies
- Interventions
- VBC101
- Drug
- Lead sponsor
- VelaVigo Bio Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas + 2 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- TAK-188
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 15
- States / cities
- Santa Monica, California • New Haven, Connecticut • Orlando, Florida + 12 more
- Conditions
- Participants With Advanced Solid Tumor Malignancies
- Interventions
- VBC106
- Drug
- Lead sponsor
- VelaVigo Bio Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Houston, Texas • West Valley City, Utah • Fairfax, Virginia
- Conditions
- ADHD - Attention Deficit Disorder With Hyperactivity, Irritability, Aggression Childhood
- Interventions
- CNS Stimulant, Placebo, CNS Stimulant open label first phase
- Drug · Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 7 Years to 12 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Children with Medical Complexity, Child, Only, Infant Morbidity, Infant Conditions, Utilization, Health Care, Emergencies, Chronic Condition
- Interventions
- Emergency Care Action Plan
- Other
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Bipolar Depression
- Interventions
- Medtronic Percept RC System, One Month Blinded Discontinuation Period
- Device · Behavioral
- Lead sponsor
- Wayne Goodman MD
- Other
- Eligibility
- 22 Years to 64 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Houston, Texas • Seattle, Washington
- Conditions
- Hypertension
- Interventions
- optima4BP Medication Management
- Device
- Lead sponsor
- Optima Integrated Health
- Industry
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- San Carlos, California
- Conditions
- HIV Infections
- Interventions
- Protease inhibitor tipranavir
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 40 more
- Conditions
- Treatment-resistant Depression
- Interventions
- Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more